Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Taysha Gene Therapies to Participate in Upcoming September Investor Healthcare Conferences By: Taysha Gene Therapies, Inc. via Business Wire September 01, 2021 at 16:01 PM EDT Citi’s 16th Annual BioPharma Conference on September 8, 2021 Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021 at 5:00 pm ET 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021 at 1:20 pm ET HC Wainwright 23rd Annual Global Investment Conference on September 13, 2021 at 7:00 am ET SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines on September 23, 2021 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021 at 8:00 am ET Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the following investor healthcare conferences: Citi’s 16th Annual BioPharma Conference, Morgan Stanley 19th Annual Global Healthcare Conference, 2021 Wells Fargo Virtual Healthcare Conference, HC Wainwright 23rd Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference and the SVB Leerink CybeRx Series. Conferences Details: Event: Citi’s 16th Annual BioPharma Conference Date: Wednesday September 8, 2021 Format: 1x1 meetings Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Kimberly Lee, SVP, Corporate Communications and Investor Relations Event: Morgan Stanley 19th Annual Global Healthcare Conference Date: Thursday September 9, 2021 Time: 5:00 pm ET Format: Fireside chat Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Event: 2021 Wells Fargo Virtual Healthcare Conference Date: Friday September 10, 2021 Time: 1:20 pm ET Format: Fireside chat Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Event: HC Wainwright 23rd Annual Global Investment Conference Date: Monday September 13, 2021 Time: 7:00 am ET Format: Fireside chat Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Event: SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicine Date: Thursday September 23, 2021 Format: 1x1 meetings Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Kimberly Lee, SVP, Corporate Communications and Investor Relations Event: 2021 Cantor Virtual Global Healthcare Conference Date: Monday September 27, 2021 Time: 8:00 am ET Format: Fireside Chat Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005994/en/Contacts Company Contact: Kimberly Lee, D.O. SVP, Corporate Communications and Investor Relations Taysha Gene Therapies klee@tayshagtx.com Media Contact: Carolyn Hawley Canale Communications carolyn.hawley@canalecomm.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Taysha Gene Therapies to Participate in Upcoming September Investor Healthcare Conferences By: Taysha Gene Therapies, Inc. via Business Wire September 01, 2021 at 16:01 PM EDT Citi’s 16th Annual BioPharma Conference on September 8, 2021 Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021 at 5:00 pm ET 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021 at 1:20 pm ET HC Wainwright 23rd Annual Global Investment Conference on September 13, 2021 at 7:00 am ET SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines on September 23, 2021 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021 at 8:00 am ET Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the following investor healthcare conferences: Citi’s 16th Annual BioPharma Conference, Morgan Stanley 19th Annual Global Healthcare Conference, 2021 Wells Fargo Virtual Healthcare Conference, HC Wainwright 23rd Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference and the SVB Leerink CybeRx Series. Conferences Details: Event: Citi’s 16th Annual BioPharma Conference Date: Wednesday September 8, 2021 Format: 1x1 meetings Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Kimberly Lee, SVP, Corporate Communications and Investor Relations Event: Morgan Stanley 19th Annual Global Healthcare Conference Date: Thursday September 9, 2021 Time: 5:00 pm ET Format: Fireside chat Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Event: 2021 Wells Fargo Virtual Healthcare Conference Date: Friday September 10, 2021 Time: 1:20 pm ET Format: Fireside chat Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Event: HC Wainwright 23rd Annual Global Investment Conference Date: Monday September 13, 2021 Time: 7:00 am ET Format: Fireside chat Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Event: SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicine Date: Thursday September 23, 2021 Format: 1x1 meetings Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Kimberly Lee, SVP, Corporate Communications and Investor Relations Event: 2021 Cantor Virtual Global Healthcare Conference Date: Monday September 27, 2021 Time: 8:00 am ET Format: Fireside Chat Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005994/en/Contacts Company Contact: Kimberly Lee, D.O. SVP, Corporate Communications and Investor Relations Taysha Gene Therapies klee@tayshagtx.com Media Contact: Carolyn Hawley Canale Communications carolyn.hawley@canalecomm.com
Citi’s 16th Annual BioPharma Conference on September 8, 2021 Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021 at 5:00 pm ET 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021 at 1:20 pm ET HC Wainwright 23rd Annual Global Investment Conference on September 13, 2021 at 7:00 am ET SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines on September 23, 2021 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021 at 8:00 am ET
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the following investor healthcare conferences: Citi’s 16th Annual BioPharma Conference, Morgan Stanley 19th Annual Global Healthcare Conference, 2021 Wells Fargo Virtual Healthcare Conference, HC Wainwright 23rd Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference and the SVB Leerink CybeRx Series. Conferences Details: Event: Citi’s 16th Annual BioPharma Conference Date: Wednesday September 8, 2021 Format: 1x1 meetings Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Kimberly Lee, SVP, Corporate Communications and Investor Relations Event: Morgan Stanley 19th Annual Global Healthcare Conference Date: Thursday September 9, 2021 Time: 5:00 pm ET Format: Fireside chat Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Event: 2021 Wells Fargo Virtual Healthcare Conference Date: Friday September 10, 2021 Time: 1:20 pm ET Format: Fireside chat Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Event: HC Wainwright 23rd Annual Global Investment Conference Date: Monday September 13, 2021 Time: 7:00 am ET Format: Fireside chat Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Event: SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicine Date: Thursday September 23, 2021 Format: 1x1 meetings Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Kimberly Lee, SVP, Corporate Communications and Investor Relations Event: 2021 Cantor Virtual Global Healthcare Conference Date: Monday September 27, 2021 Time: 8:00 am ET Format: Fireside Chat Participants: RA Session II, President, Founder and CEO Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005994/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate Communications and Investor Relations Taysha Gene Therapies klee@tayshagtx.com Media Contact: Carolyn Hawley Canale Communications carolyn.hawley@canalecomm.com